Evidence map›Paper›PMID 37122731›Full record

ArticleFrontiers in immunology2023

Bioactive compound C498-0670 alleviates LPS-induced sepsis

Jing Xu, Xinxin Zhang, Mingming Zhou, Peizhe Lu, Yuting Xu, Lihong Wu, Qianyue Zhang, Zhihua Wu, Xiaoyu Xu, Pengfei Shi and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Jing XuDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Xinxin ZhangInnovation Platform of Marine Drug Screening & Evaluation, Qingdao Pilot National Laboratory for Marine Science and Technology, Qingdao, Shandong, China.
Mingming ZhouInnovation Platform of Marine Drug Screening & Evaluation, Qingdao Pilot National Laboratory for Marine Science and Technology, Qingdao, Shandong, China.
Peizhe LuDepartment of Neuroscience, University of Michigan, Ann Arbor, MI, United States.
Yuting XuKey Laboratory of Marine Drugs, Ministry of Education of China, School of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
Lihong WuKey Laboratory of Marine Drugs, Ministry of Education of China, School of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
Qianyue ZhangKey Laboratory of Marine Drugs, Ministry of Education of China, School of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
Zhihua WuInnovation Platform of Marine Drug Screening & Evaluation, Qingdao Pilot National Laboratory for Marine Science and Technology, Qingdao, Shandong, China.
Xiaoyu XuCollege of Marine Life Sciences, Ocean University of China, Qingdao, China.
Pengfei ShiInnovation Platform of Marine Drug Screening & Evaluation, Qingdao Pilot National Laboratory for Marine Science and Technology, Qingdao, Shandong, China.
Qingda WeiSchool of Medicine, Zhengzhou University, Zhengzhou, China.
Xiaoyu LiDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Qiaoling SongInnovation Platform of Marine Drug Screening & Evaluation, Qingdao Pilot National Laboratory for Marine Science and Technology, Qingdao, Shandong, China.
Qingdao National Laboratory for Marine Science and Technology · CNOcean University of China · CNQingdao University · CNUniversity of Michigan · USZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The JAK/STAT and NFκB signaling pathways are two major inflammatory signaling pathways that are usually activated simultaneously in the body's inflammatory response to bacterial or viral infections. Hyperactivation of these two prominent signaling pathways is associated with various immune-related diseases and mortality, pointing to an urgent need for drug development targeting JAK/STAT and/or NFκB signaling. In this study, we screened 18,840 compounds using our well-established dual STAT-NFκB driven luciferase reporter based high-throughput screening system and identified a bioactive compound C498-0670, which inhibits both JAK/STAT and NFκB signaling. C498-0670 inhibits the activation of STATs and p-IKKα/β in both the immortalized cell lines and primary peritoneal macrophages, while suppressing the expression of LPS-induced inflammatory mediators

Indexed as

LipopolysaccharidesShock, SepticAnimalsJanus KinasesMiceMolecular Docking SimulationNF-kappa BSignal TransductionJanus KinasesLipopolysaccharidesNF-kappa Banti-inflammatoryJAK/STATLPSNFκBseptic shocktranscriptome sequencing

Identifiers

PMID37122731
PMCPMC10140310
OpenAlexW4367601383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.